TARS: Tarsus Pharmaceuticals, Inc. Stock

by  •  • Comments Off on TARS: Tarsus Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,980.55
Enterprise Value ($M) 1,876.75
Book Value ($M) 342.46
Book Value / Share 8.15
Price / Book 5.78
NCAV ($M) 322.48
NCAV / Share 7.68
Price / NCAV 6.14

Profitability (mra)
Return on Invested Capital (ROIC) -0.25
Return on Assets (ROA) -0.30
Return on Equity (ROE) -0.38

Liquidity (mrq)
Quick Ratio 5.54
Current Ratio 5.57

Balance Sheet (mrq) ($M)
Current Assets 480.77
Assets 500.75
Liabilities 158.29
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 182.95
Operating Income -120.57
Net Income -115.55

Cash Flow Statement (mra) ($M)
Cash From Operations -83.03
Cash from Investing -199.19
Cash from Financing 154.66

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
2 days ago 13G/A Morgan Stanley 4.70 -0.01
04-24 13G/A BlackRock, Inc. 7.40 -17.65
02-13 13G/A Cowen Financial Products LLC 4.90 -0.11
11-14 13G/A Cormorant Asset Management, LP 1.31 -77.49
11-14 13G/A Paradigm Biocapital Advisors LP 6.40 26.61
11-14 13G Prudential Financial Inc 6.00
11-12 13G Jennison Associates Llc 5.70
11-12 13G/A Vanguard Group Inc 5.51 0.00
11-06 13G/A Frazier Life Sciences IX, L.P. 4.20 12.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-08 138,781 581,132 23.88
2025-05-07 100,842 310,716 32.45
2025-05-06 96,933 427,016 22.70
2025-05-05 202,053 648,639 31.15

(click for more detail)

Similar Companies
SVRA – Savara Inc. SWTX – SpringWorks Therapeutics, Inc.
SYRE – Spyre Therapeutics, Inc. TECH – Bio-Techne Corporation
TERN – Terns Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io